Fluency | Jotup

Fluent, Inc. to Announce Second Quarter Financial Results on August 9, 2022

Retrieved on:

Thursday, August 4, 2022

Company, Technology, Webcast, Fluency, GLOBE, NASDAQ, Online shopping

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc.(NASDAQ: FLNT), a leading data-driven performance marketing company, announced today that it will report its financial results for the second quarter 2022 after the close of the U.S. financial markets on August 9, 2022.

Key Points:

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc.(NASDAQ: FLNT), a leading data-driven performance marketing company, announced today that it will report its financial results for the second quarter 2022 after the close of the U.S. financial markets on August 9, 2022.
The Company will host a conference call on August 9, 2022, at 4:30pm ET to review its second quarter 2022 financial results and provide a business update.
To listen to the telephone replay, please dial 1(800) 770-2030 or 1(647) 362-9199 with the replay passcode 6292663.
Fluent, Inc. (NASDAQ: FLNT) is a global data-driven performance marketing company and trusted growth partner for leading brands.

Fluent BioSciences launches industry's most accessible, cost-effective and scalable technology (PIPseqTM) to accelerate adoption of single-cell RNA sequencing in any laboratory

Retrieved on:

Thursday, June 23, 2022

WATERTOWN, Mass., June 23, 2022 /PRNewswire/ -- Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced the launch of two new breakthrough products for 3′ single-cell RNA analysis. Scaled to efficiently fit diverse experimental demands, PIPseq T2 and T20 v3.0 kits capture up to 2,000 and 20,000 single cells or nuclei per reaction, respectively. In addition, Fluent announces early access for higher scale T200 kits, to enable studies up to 200,000 cells in a single sample, as well as an Epitope Sequencing Kit for multi-omics applications.

Key Points:

In addition, Fluent announces early access for higher scale T200 kits, to enable studies up to 200,000 cells in a single sample, as well as an Epitope Sequencing Kit for multi-omics applications.
"Fluent BioSciences is breaking down the barriers to entry in the single-cell market with our ground-breaking PIPseq technology and products" stated Sepehr Kiani, co-founder, and CEO of Fluent BioSciences.
Researchers are invited to contact Fluent to learn more about the early access programs or applying PIPseq to their biological question of interest.
Fluent BioSciences is a privately funded biotechnology company with a mission to accelerate the understanding of biology and disease through accessible, affordable, and scalable solutions for every laboratory from research to the clinic.

World Food Program USA Appoints Cargill and Kastner Executives to its Board of Directors

Retrieved on:

Thursday, June 23, 2022

World Food Program USA has grown dynamically in recent years to meet the urgent needs of the United Nations World Food Programme.

Key Points:

World Food Program USA has grown dynamically in recent years to meet the urgent needs of the United Nations World Food Programme.
As industry leaders in their respective fields of agribusiness and advertising, Cruz and Rochon are well positioned to support World Food Program USA at this time of unprecedented need.
Cargill is a longtime partner of World Food Program USA, generously supporting school meal programs, farmer training and emergency relief efforts.
"For over 20 years, Cargill and World Food Program USA have led efforts that address food insecurity and improve farmer livelihoods around the world.

Fluent BioSciences and NanoCellect announce joint collaboration to improve resolution of single-cell RNA sequencing analysis of rare cell populations

Retrieved on:

Friday, June 17, 2022

Solution, Time, RNA, WOLF, Science, B cell, Technology, Neuroscience, CEO, Efficiency, Research, Protein, Drug discovery, Single-cell analysis, Organic acid, Cell, Vaccine, Fine chemical, Fluency

WATERTOWN, Mass., June 17, 2022 /PRNewswire/ -- Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations.

Key Points:

WATERTOWN, Mass., June 17, 2022 /PRNewswire/ -- Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations.
"I am very pleased that Fluent and NanoCellect are able to leverage and combine the unique advantages of our respective technologies to expand the use of single-cell RNA sequencing for rare cell populations."
"Reliable and reproducible sample preparation is critically important to the scRNAseq workflow" stated Jose Morachis, Ph.D., President and co-founder at NanoCellect.
NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research.

Cansortium Files its 2021 Audited Financial Statements as well as its First Quarter 2022 Interim Unaudited Financial Statements on SEDAR

Retrieved on:

Friday, June 10, 2022

FY 2021 Financial Highlights (vs. FY 2020)

Key Points:

FY 2021 Financial Highlights (vs. FY 2020)
Revenue increased 25% to $65.4 million compared to $52.4 million.
Adjusted gross profit1 increased 34% to $41.9 million or 64.1% of revenue, compared to $31.4 million or 59.9% of revenue.
The Company continues to expect revenue in 2022 to range between $90-$95 million, reflecting an approximate 40% increase from 2021.
Cansortium also expects adjusted EBITDA in 2022 to range between $25-$28 million, reflecting an approximate 35% increase from 2021.

Cansortium Provides Bi-Weekly MCTO Status Update and Update Regarding Annual and Interim Financial Statements

Retrieved on:

Wednesday, June 8, 2022

Mission statement, CFO, CSE, Company, OSC, Product requirements document, OTCQX, Ontario Securities Commission, CEO, News, Annual Filing Season Program, NP, National Policy, Phrase, Fluency, Originality, Requirement, Drug, Risk management

The MCTO does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

Key Points:

The MCTO does not affect the ability of other shareholders, including the public, to trade in securities of the Company.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan (through its in-market partner) and Texas.
In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information.
Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates, and projections regarding future events.

Cansortium Provides Bi-Weekly MCTO Status Update and Update Regarding Interim Financial Statements

Retrieved on:

Friday, May 27, 2022

The MCTO does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

Key Points:

The MCTO does not affect the ability of other shareholders, including the public, to trade in securities of the Company.
The Company expects the Interim Filings to be filed concurrently with the Annual Filings on June 8, 2022.
In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information.
Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates, and projections regarding future events.

Fluent, Inc. to Host 2022 Annual Meeting of Shareholders

Retrieved on:

Wednesday, May 25, 2022

Investor relations, NASDAQ, Fluency, Webcast, GLOBE, Technology, EST, Annual general meeting, Online shopping

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc.(NASDAQ: FLNT), a leading data-driven performance marketing company, announced today that it will host its 2022 Annual Meeting of Shareholders on Wednesday, June 8, 2022 at 11 a.m. EST in a virtual-only format.

Key Points:

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc.(NASDAQ: FLNT), a leading data-driven performance marketing company, announced today that it will host its 2022 Annual Meeting of Shareholders on Wednesday, June 8, 2022 at 11 a.m. EST in a virtual-only format.
Shareholders of record as of the close of business on May 6, 2022 can attend the virtual annual meeting by using the 16-digit control number included on the proxy card, voting instruction form or notice.
Shareholders who do not intend to vote or submit a question during the virtual meeting and other interested parties may access the meeting as guests.
Fluent, Inc. (NASDAQ: FLNT) is a global data-driven performance marketing company and trusted growth partner for leading brands.

Cansortium Provides Bi-Weekly MCTO Status Update

Retrieved on:

Thursday, May 19, 2022

Company, Fluency, NP, Requirement, Product requirements document, News, Originality, National Policy, Ontario Securities Commission, CSE, OSC, CFO, Phrase, OTCQX, CEO, Drug, Risk management

MIAMI, May 19, 2022 /PRNewswire/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent brand, is providing a bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders ("NP 12-203").

Key Points:

MIAMI, May 19, 2022 /PRNewswire/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent brand, is providing a bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders ("NP 12-203").
The MCTO does not affect the ability of other shareholders, including the public, to trade in securities of the Company.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan and Texas.
Cansortium Inc.'s common shares trade on the CSE under the symbol "TIUM.U" and on the OTCQX Best Market under the symbol "CNTMF".

Fluent, Inc. to Present at the 17th Annual Needham Technology & Media Conference

Retrieved on:

Friday, May 13, 2022

Internet, Company, Fluency, Private Securities Litigation Reform Act, NASDAQ, PSLRA, Conference, Technology, Mission statement, Press, SEC, Risk, Annual report, GLOBE, Public relations

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc.(NASDAQ: FLNT), a leading data-driven performance marketing company, today announced that it will participate in the 17th Annual Needham Technology & Media Conference being held on May 19, 2022.

Key Points:

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Fluent, Inc.(NASDAQ: FLNT), a leading data-driven performance marketing company, today announced that it will participate in the 17th Annual Needham Technology & Media Conference being held on May 19, 2022.
Don Patrick, Fluents Chief Executive Officer, Ryan Schulke, Fluents Chief Strategy Officer, and Sugandha Khandelwal, Fluents Chief Financial Officer, are scheduled to present on Thursday, May 19 at approximately 11:45am Eastern time.
A replay of the broadcast will be available on the website until May 19, 2023.
Experts in creating value for consumers, Fluent leverages its consumer database, digital media portfolio, and proprietary data science and technology to deliver outcome-based solutions for marketers.